| Updated:
Pfizer pulls out of drug trials
Pfizer has halted patient enrolment in a late-stage lung cancer trial of its experimental drug, figitumumab, for safety reasons.
The decision was recommended by independent safety monitors overseeing the study. In their review, the monitors found more serious adverse events, including deaths, with patients receiving figitumumab.
Pfizer said currently enrolled patients may continue their treatment in consultation with their physicians. As of 30 September, 681 patients were enrolled in the Phase 3 study out of a target of 820.